Brief: Sab Biotherapeutics - ‍​Grade 3 Or Higher Treatment Emergent Adverse Event Rates Were Similar Between Sab-185 And Regen-Cov Arms

SAB Biotherapeutics

26/04/2023 13:30

April 26 (Reuters) - SAB Biotherapeutics Inc  SABS.O :
    * SAB BIOTHERAPEUTICS ANNOUNCES POSITIVE RESULTS FROM PHASE
3
TRIAL OF SAB-185 IN PATIENTS WITH COVID-19 AT HIGH-RISK FOR
SEVERE COMPLICATIONS
    * SAB BIOTHERAPEUTICS - SAB-185 DEMONSTRATED BENEFIT IN
SUSTAINED
SYMPTOM RESOLUTION IN PATIENTS WITH OMICRON VARIANTS OF
SARS-COV-2
    * SAB BIOTHERAPEUTICS - ‍​GRADE 3 OR HIGHER TREATMENT
EMERGENT
ADVERSE EVENT RATES WERE SIMILAR BETWEEN SAB-185 AND REGEN-COV
ARMS

Source text for Eikon:  ID: 
Further company coverage:  SABS.O 

 ((Reuters.Briefs@thomsonreuters.com;))